Team,
After the meeting yesterday evening with our consulting team I have several points of interest I'd like to personally address today as we look to take the finals steps towards a decision in regards to our clinical trial management process. Personally, I believe the consulting team we brought in to direct us towards the best possible solution for the topic at hand provided keen insights, particularly in the application and implementation of Electronic Data Capture, that we could utilize in making our final decision for sustainable growth in the health care segment. After looking back at my initial research that I posted prior to the consultant meeting and my notes from the meeting I see that the consulting team discussed and verified virtually all of the benefits of EDC and my initial assessment of moving forward in that direction. I do, however feel as though the consulting team could have advised us on the other alternatives besides EDC in greater detail. For instance they consulted our leadership team in regards to the digital imagining solution, but neglected to advise us on the possible alternative of improving our current paper-based process. Although I agreed with their end recommendation of implementing EDC to move the business process forward, I do believe they were 'selling' this application and lacked the advice on the possible risks associated with EDC. Undoubtedly there is a difference between risk and return. It would have been in the team's interest to acknowledge the inherited risk of investing in a relatively new and unproven system as well as a young firm in Phase Forward that has the potential to have a 'bubble' associated with the web-based technology. The return, or ceiling, for viable, sustainable growth in our health care segment is certainly greater with the implementation of EDC in place of the paper-based system, however there is a great risk that accompany's the use of this new system as compared the current paper-based system that has been in place and is proven to work for years.
Due to the fact that the greatest cost savings and growth lies in shortening the length of time to finalize our clinical trials, I believe it is worth the risk to invest in Phase Forward and the implementation of EDC. Improving our current paper-based system is worth discussing in greater detail, while we should rule out the alternative situation of digital imaging to due to the massive investment costs of storage space.
Regards,
Brian Grau
No comments:
Post a Comment